Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease.

de Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Tsui W, Saint Louis LA, Sobanska L, Brys M, Li Y, Rich K, Rinne J, Rusinek H.

Ann N Y Acad Sci. 2007 Feb;1097:114-45. Review.

PMID:
17413016
2.

MRI and CSF studies in the early diagnosis of Alzheimer's disease.

de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H.

J Intern Med. 2004 Sep;256(3):205-23.

3.
4.

2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Green RC, Harvey D, Jack CR, Jagust W, Luthman J, Morris JC, Petersen RC, Saykin AJ, Shaw L, Shen L, Schwarz A, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jun;11(6):e1-120. doi: 10.1016/j.jalz.2014.11.001. Review.

5.

Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.

Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, Kemppainen N, Någren K, Kim BC, Tsui W, de Leon MJ.

Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2169-81. doi: 10.1007/s00259-008-0833-y. Epub 2008 Jun 20.

6.
7.

Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.

Susanto TA, Pua EP, Zhou J; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;45(1):253-68. doi: 10.3233/JAD-142451.

PMID:
25524955
8.

Linking brain imaging and genomics in the study of Alzheimer's disease and aging.

Reiman EM.

Ann N Y Acad Sci. 2007 Feb;1097:94-113. Review.

PMID:
17413015
9.

Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers.

Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE, Doraiswamy PM; Alzheimer’s Disease Neuroimaging Initiative.

Radiology. 2013 Feb;266(2):583-91. doi: 10.1148/radiol.12120010. Epub 2012 Dec 11.

10.

Multimodal classification of Alzheimer's disease and mild cognitive impairment.

Zhang D, Wang Y, Zhou L, Yuan H, Shen D; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2011 Apr 1;55(3):856-67. doi: 10.1016/j.neuroimage.2011.01.008. Epub 2011 Jan 12.

11.

Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease.

Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, Rich K, Kim BC, Mehta P, Zinkowski R, Pratico D, Wallin A, Zetterberg H, Tsui WH, Rusinek H, Blennow K, de Leon MJ.

J Alzheimers Dis. 2009;16(2):351-62. doi: 10.3233/JAD-2009-0968.

12.

Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease.

Schmand B, Huizenga HM, van Gool WA.

Psychol Med. 2010 Jan;40(1):135-45. doi: 10.1017/S0033291709991516. Epub 2009 Oct 29.

PMID:
19863841
13.

Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).

de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, Tsui W, Kandil E, Scherer AJ, Roche A, Imossi A, Thorn E, Bobinski M, Caraos C, Lesbre P, Schlyer D, Poirier J, Reisberg B, Fowler J.

Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10966-71. Epub 2001 Aug 28.

14.

Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.

Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G.

J Nutr Health Aging. 2008 Jan;12(1):61S-5S.

PMID:
18165848
15.

Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.

Jack CR Jr, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Cha RH, Tangalos EG, Petersen RC.

Neurology. 2004 Feb 24;62(4):591-600.

16.

Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging.

Chetelat G, Baron JC.

Neuroimage. 2003 Feb;18(2):525-41.

PMID:
12595205
17.

Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis.

Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, Li Y, Boppana M, de Leon MJ.

Neurology. 2005 Jun 14;64(11):1860-7.

PMID:
15955934
18.

Early detection of Alzheimer's disease using neuroimaging.

Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ.

Exp Gerontol. 2007 Jan-Feb;42(1-2):129-38. Epub 2006 Jul 12. Review.

PMID:
16839732
19.

The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, Jack CR Jr, Sperling R, Cummings J, Blennow K, O'Bryant S, Frisoni GB, Khachaturian A, Kivipelto M, Klunk W, Broich K, Andrieu S, de Schotten MT, Mangin JF, Lammertsma AA, Johnson K, Teipel S, Drzezga A, Bokde A, Colliot O, Bakardjian H, Zetterberg H, Dubois B, Vellas B, Schneider LS, Hampel H.

J Prev Alzheimers Dis. 2014 Dec;1(3):181-202.

20.

Hippocampal formation glucose metabolism and volume losses in MCI and AD.

De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Roche A, Tsui WH, Kandil E, Boppana M, Daisley K, Wang GJ, Schlyer D, Fowler J.

Neurobiol Aging. 2001 Jul-Aug;22(4):529-39.

PMID:
11445252

Supplemental Content

Support Center